Asthma is a chronic heterogeneous lung disease that encompasses several endotypes and represents a growing medical challenge worldwide. 1 It is characterized by airway hyperresponsiveness and inflammation, leading to reversible airway obstruction. 2, 3 Aberrant T H 2 cell responses against inhaled environmental allergens contribute to the pathogenesis of the allergic type of asthma and are associated with a lack and/or dysregulation of immune tolerance in the airways. 4 Growing evidence suggests that therapeutic transfer of dendritic cells (DCs) with immunoregulatory properties suppresses pathogenic T H 2 effector responses and prevents or even reverses established airway inflammation in experimental asthma. 5, 6 Still, tolerogenic DC responses are often impaired or overridden in human patients with asthma. 7 Therefore the identification of mechanisms that can induce, restore, or both tolerogenic DC functions in the airways is essential for the development of new therapeutic approaches for the growing number of asthmatic patients.
Tolerogenic DCs are generated through exposure to immunoregulatory cytokines, such as IL-10 and TGF-b; pathogens; immune-modulating pharmacologic agents; and genetic modifications. 8 Elegant studies, mainly in the context of self-antigen-driven T-cell stimulation, have demonstrated that regulatory T (Treg) cells endow conventional dendritic cells (cDCs) with tolerogenic functions that suppress T H 1 and T H 17 10 Finally, functional interactions of Foxp3 1 Treg cells with cDCs decreased their immunostimulatory potential and induced the generation of IL-10-producing T R 1-like cells that inhibited encephalitogenic T-cell responses in patients with experimental autoimmune encephalomyelitis, a mouse model of multiple sclerosis. 11 Nevertheless, the effects of Treg cells on modulation of DC functions in the context of allergen-driven T H 2 responses and ensuing airway inflammation remain largely unexplored. Moreover, the transcriptional networks through which Treg cells instruct the generation of DCs with tolerogenic properties are elusive.
Previously, we have demonstrated that the cytokine activin-A induces generation of Foxp3 2 IL-10-producing Treg cells, which exhibit robust suppressive functions toward allergen-induced naive and T H 2 effector responses. Notably, therapeutic administration of Act-A-iTreg cells in ovalbumin (OVA)-induced allergic airway inflammation conferred significant protection against asthma manifestations associated with markedly decreased frequencies of activated CD11c 1 MHC class II (MHCII) high cDCs in the lung-draining mediastinal lymph nodes (LNs). 12 On the basis of these findings, we hypothesized that Act-A-iTreg cells can suppress DC responses in vivo and endow them with enhanced tolerogenic functions. Untangling the disease-modulating interactions between Act-A-iTreg cells and DCs might facilitate the design of novel DC-based immunotherapies for the re-establishment of tolerance in the airways.
Here we demonstrate that Act-A-iTreg cell-modified DCs exhibit a significantly impaired capacity to uptake allergen and traffic to the draining lymph nodes (DLNs) accompanied by a markedly decreased ability to elicit T H 2 responses in vivo. Genome-wide transcriptional profiling revealed that Act-A-iTreg cells inhibit the expression of key T H 2 cell-skewing signals in DCs. Of clinical relevance, vaccination of allergic mice with Act-A-iTreg cell-modified DCs protected against experimental asthma through the generation of Foxp3
1 Treg cells in a feed-forward immunoregulatory circuit. Mechanistically, our studies revealed that programmed death protein 1 (PD-1)/programmed death ligand 1 (PD-L1) interactions were essential for the generation of DCs with tolerogenic properties by Act-A-iTreg cells. Collectively, our findings highlight a novel critical role for Act-A-iTreg cells in potentiating the generation of tolerogenic DCs, which can be harnessed for the control of excessive T H 2-driven airway inflammation and linked asthmatic disease.
METHODS Mice
Mice were maintained at the Animal Facility of Biomedical Research Foundation of the Academy of Athens. BALB/c, BALB/c-Rag-1 2/2 , and OVA-specific T-cell receptor2transgenic DO11.10 mice were purchased from the Jackson Laboratory (Bar Harbor, Me). DO11.10 BALB/ c-Rag-1 2/2 mice were generated by crossing DO11.10 mice with BALB/ 
Generation of OVA-primed Act-A-iTreg cells and Teff cells
BALB/c mice were immunized intraperitoneally with OVA in aluminum hydroxide (alum; Serva Electrophoresis, Heidelberg, Germany). DLN cells were harvested on day 12 and restimulated with 125 mg/mL OVA in the presence of PBS (Teff cells) or 50 ng/mL recombinant activin-A (Act-A-iTreg cells; R&D Systems, Minneapolis, Minn) for 3 days, as previously described.
12 CD4 1 T cells were isolated from cultures by using Dynabeads (Invitrogen, Carlsbad, Calif).
Generation of Act-A-iTreg or Teff cell-modified DCs
Act-A-iTreg or Teff cells, generated as previously described, 12 were transferred intraperitoneally into BALB/c-Rag1 2/2 mice (3 3 10 6 cells per mouse), followed by OVA/alum immunization. Twenty-four hours later, CD11c 1 cells were isolated from DLNs by using the mouse CD11c
MicroBeads isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany). As a control group, OVA-pulsed DCs isolated from the DLNs of nonreconstituted BALB/c-Rag1 2/2 mice were used. In other experiments BALB/c-Rag1 2/2 mice transferred with Act-A-iTreg or Teff cells were immunized intraperitoneally with OVA-Alexa Fluor 488 (Invitrogen)/alum. Twenty-four hours later, DLN cells were harvested, stained, and analyzed by using flow cytometry. 
T-cell stimulation assays

Adoptive transfer experiments
In preventive protocols OVA-pulsed Act-A-Treg or Teff cell-modified DCs (3 3 10 5 ) were transferred intraperitoneally to BALB/c mice before OVA/alum sensitization. In therapeutic protocols OVA-pulsed Act-A-Treg or Teff cell-modified DCs (3 3 10 5 ) were transferred intraperitoneally to sensitized BALB/c mice before allergen inhalation challenge. Mice received 2 challenges with aerosolized OVA (5% for 20 minutes). BALB/c-Rag1
mice were administered intraperitoneal anti-PD-1 antibody (75 mg per mouse) or immunoglobulin control 1 day before Act-A-iTreg or Teff cell administration and again on days 1 and 3 until OVA/alum immunization. Act-A-iTreg or Teff cells were also pretreated with anti-PD-1 antibody (20 mg/mL) or immunoglobulin before transfer. CD11c
1 DCs were isolated from the DLNs, pulsed with OVA, and transferred into BALB/c mice. Recipient mice were sensitized to OVA/alum.
Experimental protocol of OVA-induced allergic airway inflammation
Acute allergic airway inflammation was induced, as previously described.
12,14
Bronchoalveolar lavage analysis
Bronchoalveolar lavage (BAL) fluid harvesting was performed, as previously described. 12, 14 Inflammatory cells were obtained by means of cannulation of the trachea and lavage of the airway lumen with PBS. BAL fluid cells were counted and analyzed for viability by means of Trypan blue exclusion. BAL fluid was kept at 2808C until use.
Lung histology
Paraffin-embedded sections (4 mm) were stained with hematoxylin and eosin to evaluate lung infiltration. 12, 14 Goblet cells were counted on periodic acid-Schiff-stained lung sections by using an arbitrary scoring system. 12, 14 Cytokine analysis Cytokines were measured in culture supernatants and BAL fluid by using commercially available ELISA kits (R&D Systems).
Determination of serum antibody concentrations
OVA-specific serum antibody levels were measured by using a commercially available ELISA kit (BioLegend, San Diego, Calif). 
Foxp3 Treg cell depletion
Quantitative real-time PCR
Total RNA was isolated in TRI Reagent (Molecular Research Center, Cincinnati, Ohio) and reverse transcribed with Superscript II (Invitrogen), according to the manufacturer's recommendations. RNA samples were treated with RQ1 RNase-Free DNase (Promega, Madison, Wis) before reverse transcription to eliminate contaminating genomic DNA. Gene expression was analyzed by using SYBR Green Master mix and selected primers (see Table E1 in this article's Online Repository at www.jacionline.org). The relative expression of genes over the expression of Gapdh and Polr2a was calculated by using the 2 2DDCt analysis method. 16 RNA sequencing and bioinformatics analysis RNA sequencing (RNA-Seq) libraries were generated by using the Illumina TruSeq RNA Library Preparation Kit v2 (Illumina, San Diego, Calif), and sequencing was implemented with HiSeq 2000 by the European Molecular Biology Laboratory (EMBL). Two biological replicates were used for each condition. Fastq raw read files were adapter clipped by using cutadapt and quality trimmed by using samtools, allowing a minimum of 20 bases per read. Reads were then mapped uniquely to the UCSC hg19 reference genome by using tophat2 with default settings. 17 The uniquely aligned reads were processed for differential expression analysis by using the Bioconductor package metaseqR. 18 Reads were counted on the Ensembl exon set, and the resulting gene count table was normalized by using edgeR (''Trimmed Mean of M-values'' [TMM] method). 19 Genes with (1) length of less than 500 bp and (2) average read counts per 100 bp of less than 0.25 quantile of the average normalized read count distribution per 100 bp in the gene body were excluded to avoid possible statistical artifacts. DESeq and NOISeq were combined for differential expression analysis, providing results with log 2 (fold change [FC] ) of greater than 1 and metaseqR of less than 0.05. 20 Transcription factor (TF) motif enrichment on the differential expression gene list was estimated by using GATHER with the TRANScription FACtor J ALLERGY CLIN IMMUNOL VOLUME 141, NUMBER 2 database (TRANSFAC) option. 21 The gene networks were generated through use of Ingenuity Pathway Analysis (IPA; Qiagen, Hilden, Mass).
Statistical analysis
Statistical analyses were performed with the GraphPad Prism (Version 5; GraphPad Software, La Jolla, Calif). To calculate differences between groups, we used the Student t test, and data were logarithmized to calculate absolute values. We considered any difference with a P value of .05 or less to be statistically significant.
RESULTS
Act-A-iTreg cells inhibit the capacity of DCs to prime T H 2 responses in vivo
To delineate the effects of Act-A-iTreg cells exclusively on DCs, we established an in vivo system in which we transferred allergen (OVA)-primed Act-A-iTreg or Teff cells 12 to BALB/ c-Rag1 2/2 mice and immunized recipients with OVA/alum (experimental protocol is shown in Fig 1, A) 
CD11c
1 DCs in mice reconstituted with Act-A-iTreg cells were significantly decreased, suggesting that Act-A-iTreg cells compromise the capacity of DCs to uptake allergen and traffic to the DLNs in vivo (see Fig E1, A) .
In view of these findings, we hypothesized that Act-A-iTreg cell-modified DCs might display a decreased potential to elicit T H 2 priming on allergen stimulation. To address this, we isolated CD11c 1 DCs from the DLNs of mice reconstituted with Act-A-iTreg or Teff cells, pulsed them with OVA, and cocultured them with OVA-specific T-cell receptor2transgenic CD4 1 T responders (referred to as KJ1-26 1 cells) obtained from DO11.10 mice (experimental protocol is shown in Fig 1, A) . Our findings revealed that allergen-pulsed Act-A-iTreg cellmodified DCs exhibited a dramatically decreased capacity to stimulate proliferative responses of KJ1-26
1
CD4
1 T cells compared with Teff cell-modified DCs (see Fig E1, B) . This was accompanied by a severely compromised ability to induce T H 2 cytokine release in culture supernatants (see Fig E1, B) . Results were pooled from 2 independent experiments (n 5 3-4 mice per group). Statistical analysis was obtained by using the Student t test: **P < .01 and ***P < .001.
A key feature of tolerogenic DC subsets is their ability to suppress T H cell activation and effector function. 22, 23 Hence we explored whether Act-A-iTreg cell-modified DCs could exert functional suppression to allergen-driven T-cell responses in vivo. Remarkably, DLN T cells obtained from BALB/c mice that received Act-A-iTreg cell-modified DCs exhibited significantly decreased proliferative responses on restimulation with allergen ex vivo, whereas T cells isolated from recipients of Teff cell-modified DCs had heightened proliferative capacities (Fig 1, B) . Moreover, the T H 2 cytokine response was nearly abolished in culture supernatants, suggesting that Act-A-iTreg cell-modified DCs can suppress T H 2 cell priming in vivo (Fig 1, B) .
Notably, we observed a significant increase in the frequencies of CD4 (Fig 2, A) . In addition, on a per-cell basis, I-A d , CD80, and CD86 expression, as reflected by mean fluorescence intensity, was significantly lower in Act-A-iTreg cell-modified DCs (Fig 2, A) . In concordance with their decreased trafficking to the DLNs, Act-A-iTreg cell-modified DCs displayed low levels of CCR7, the LN homing receptor. 24 Investigation of well-known tolerogenic DC markers revealed that Act-A-iTreg cell-modified DCs expressed high levels of PD-L1, whereas ICOS ligand, galectin-1, and IDO were expressed at equivalent levels with Teff cell-modified DCs (Fig 2, A , and data not shown).
On the basis of these findings, we reasoned that Act-A-iTreg cell-modified DCs would have a diminished capacity to respond to maturation stimuli in vivo (experimental protocol is shown in Fig E3, A, in this article's Online Repository at www.jacionline.org). Indeed, CD11c
1 DCs in the DLNs of mice transferred with Act-A-iTreg cells and exposed to LPS released significantly decreased levels of TNF-a, IL-6, IL-12, and IL-10 in culture supernatants accompanied by lower expression of TNF-a, IL-6, and IL-10 mRNA (Fig 2, B and C). Moreover, the percentages of I-A d1 and CD80 1 cells among CD11c
1 DCs in mice transferred with Act-A-iTreg cells were decreased compared with those in recipients of Teff cells (see Fig E3, B) .
Taken together, these findings provide evidence that Act-A-iTreg cell-modified DCs are rendered hyporesponsive on exposure to maturation stimuli in vivo.
Act-A-iTreg cells alter T H 2-skewing transcriptional networks in DCs
To gain further insight into the molecular pathways underlying the enhanced tolerogenic functions of Act-A-iTreg cell-modified DCs, we compared their global gene expression profile to that of Teff cell-modified DCs by using RNA-Seq analysis. Notably, our findings demonstrated that Act-A-iTreg cell-modified DCs exhibited a considerably different transcriptome to that of Teff cell-modified DCs, with 639 genes being differentially regulated (absolute log 2 [FC] > _ 1 and P < _ .05), 485 of which were downregulated and 154 were upregulated (see Fig E4, A, in this article's Online Repository at www.jacionline.org). Volcano plot analysis revealed that Act-A-iTreg cells induced substantial changes in the transcriptional signature of DCs, with nearly 80% of the total differentially expressed genes showing a difference in expression greater than 2-fold (P < .05, log 2 [FC] < 21 or > 1; Fig 3, A) . These belonged to biologically important gene families, including chemokines/cytokines or their receptors, TFs, and surface receptors. Specifically, a large array of T H 2-related genes, including TFs (Klf4, Fos, Nr4a1, and Egr1), chemokines and cytokines (Ccl4, Ccl3, Ccl24, Il10, and Il4), chemokine receptors (Ccr4 and Ccr3), and other effector molecules (Chi3l3, Mmp8, and Arg1), were significantly downregulated in Act-A-iTreg cell-modified DCs (Fig 3, B) . We did not observe significant differences in the expression of the Cd80 and Cd86 in the 2 groups studied (log 2 [FC] 5 0.657 and 0.602, respectively), whereas Ccr7 was marginally upregulated (log 2 [FC] 5 1.073). Notably, genes associated with T H 1, T H 17, and T R 1 cell-associated responses, including Il12b, Il23r, Ahrr, Cx3cl1, Gzmb, Stat4, Tnfsfr11a, and Il31ra, were enriched in Act-A-iTreg cell-modified DCs (Fig 3, B) .
Subsequently, we performed bioinformatics analysis to explore the effects of Act-A-iTreg cells on the regulation of T H 2-associated transcriptional nodules in DCs. IPA identified gene networks representing the intermolecular connections among the differentially expressed genes in Act-A-iTreg cell-modified DCs. One of the top IPA-generated networks identified strong correlations between TF genes that participate in DC development, differentiation, and effector function (eg, Klf4, Lef1, Myc, Hes1, Notch1, and Notch3; Fig 3, C) . IPA also demonstrated that Act-A-iTreg cell-modified DCs exhibited significantly lower expression of genes associated with T H 2 cytokine signaling (see Fig E4, B) . Subsequently, we used GATHER to explore TF motif enrichment among the differentially expressed genes, aiming to identify the most relevant TF associated with target gene regulation. 21 Our data showed that nuclear factor kB, Mothers against decapentaplegic homolog 4 (Smad-4), and the Wnt signaling-related TFs transcription factor E2-alpha (TCF-3) and myoblast determination protein 1 (Myod-1) were among the top predicted to regulate several of the differentially expressed genes in Act-A-iTreg cell-modified DCs (Fig 3, D) .
We next validated our RNA-Seq findings using quantitative RT-PCR analysis. Indeed, the mRNA levels of Ccl4, Ccr3, Ccr4, Kr€ uppel-like factor 4 (KLF4), NUR77 (encoded by Nr4a1), Egr-1, c-Myc, c-Fos, and HES-1 were significantly decreased in Act-A-iTreg cell-modified DCs (Fig 3, E and F) . In contrast, C-Rel, the Aryl hydrocarbon receptor repressor (encoded by Ahrr), and Cx3cl1 were upregulated in Act-A-iTreg cellmodified DCs (Fig 3, E) . Considering that our RNA-Seq analysis uncovered dysregulation among several genes associated with T H 2-instructive programs in Act-A-iTreg cell-modified DCs, we examined whether expression of other T H 2-related genes was also suppressed. Indeed, interferon regulatory factor 4 (IRF4), Ccl17, IL-5, and IL-33 mRNA levels were significantly decreased in Act-A-iTreg cell-modified DCs, whereas levels of lymphoid enhancer-binding factor 1, the Wnt signaling-related TF, were increased (Fig 3, F) .
In summary, our findings propose that Act-A-iTreg cells alter the DC transcriptional profile, diminishing the expression of key T H 2-skewing networks.
In vivo administration of Act-A-iTreg cell-modified DCs reverses established allergic inflammation and protects against experimental asthma Building on the aforementioned observations, we hypothesized that Act-A-iTreg cell-modified DCs would restrain T H 2 effector responses and prevent the development of airway inflammation (experimental protocol is shown in Fig E5, A, in this article's Online Repository at www.jacionline.org). Indeed, administration of Act-A-iTreg cell-modified DCs induced a significant decrease in total numbers of infiltrating cells in BAL fluid and, notably, eosinophils relative to mice transferred with Teff cell-modified DCs and allergic mice (Fig 4, A) . T H 2 cytokine levels were also decreased in the BAL fluid of mice transferred with Act-A-iTreg cell-modified DCs (Fig 4, B) . Importantly, Act-A-iTreg cell-modified DCs ameliorated peribronchial inflammation and mucus secretion in the lungs, whereas mice transferred with Teff cell-modified DCs exhibited enhanced inflammatory cell infiltration (Fig 4, C) .
We next evaluated whether the ameliorated asthmatic disease features in recipients of Act-A-iTreg cell-modified DCs were associated with reduced T H 2 systemic responses in the mediastinal LNs. Indeed, DLN T cells obtained from Results are shown as means 6 SEMs (n 5 4-6 mice per group in 2 independent experiments). B, Expression of Tnfa, Il6, and Il10 was analyzed by using quantitative RT-PCR normalized to Gapdh and Polr2a expression and presented as percentage expression compared with the PBS group. Results are shown as means 6 SEMs (n 5 4-6 mice per group in 2 independent experiments). C, Cytokine release after ex vivo LPS stimulation. Results are shown as means 6 SEMs (n 5 4-6 mice per group in 2 independent experiments). Statistical significance was obtained by using the unpaired Student t test: *P < .05, **P < .01, and ***P < .001.
Act-A-iTreg cell-modified DC recipients released significantly lower amounts of IL-4, IL-13, and IL-10 on restimulation with allergen ex vivo compared with those isolated from Teff cell-modified DC recipients (Fig 4, D) . Moreover, mice transferred with Act-A-iTreg cell-modified DCs had markedly decreased OVA-specific IgE levels in the serum, a hallmark of allergic inflammation (Fig 4, E) .
Subsequently, we explored whether Act-A-iTreg cell-modified DCs could limit the severity of allergic airway disease when transferred during the phase of allergen challenge in a therapeutic regimen (experimental protocol is shown in Fig 5, A) . Remarkably, in vivo administration of Act-A-iTreg cell-modified DCs dampened the influx of infiltrating eosinophils, along with other inflammatory cells in the BAL fluid and significantly decreased T H 2 cytokine production compared with administration of Teff cell-modified DCs or allergic mice (Fig 5, B, and data not shown) . The suppressive effects of Act-A-iTreg cell-modified DCs on airway inflammation were accompanied by significantly reduced proliferative recall responses of DLN T cells to allergen and decreased IL-13 and IL-10 in culture supernatants (Fig 5, C) . Notably, OVA-specific IgE amounts were also significantly reduced in the sera of mice administered Act-A-iTreg cell-modified DCs during allergen challenge (Fig 5, D) .
Altogether, these findings provide compelling evidence that vaccination of mice with Act-A-iTreg cell-modified DCs can restrain established T H 2 allergic responses and ameliorate experimental asthma severity.
Act-A-iTreg cell-modified DCs elicit the generation of Foxp3
1 Treg cells J ALLERGY CLIN IMMUNOL VOLUME 141, NUMBER 2 inflammation, we investigated whether they could drive the generation, expansion, or both of Treg cells in vivo. To this end, we assessed the frequencies of newly generated CD4 
Foxp3-GFP
1 Treg cells in the DLNs (Fig 6, A) . 
Considering that DLNs from mice transferred with Act-AiTreg cell-modified DCs contained increased percentages of
CD4
1 responders T cells, whereas T cells obtained from mice transferred with Teff cell-modified DCs (T[Teff-DCs]) did not exhibit discernible suppressor functions (Fig 6, B) . Moreover, T(Act-A-iTreg-DCs) significantly decreased T H 2 cytokine release (Fig 6, B) . To delineate the mechanisms involved in the enhanced suppressive capacities of T(Act-A-iTeg-DCs), we added neutralizing antibodies against immunosuppressive cytokines or their signaling pathways in secondary suppressive cultures. In line with previous studies, 26 E, OVA-specific IgE levels in sera. Results are shown as means 6 SEMs of triplicate wells from 2 independent experiments (n 5 5-7 mice per group). Statistical significance was obtained by using the unpaired Student t test: *P < .05, **P < .01, and ***P < .001.
major effect on the suppressive effects of T(Act-A-iTreg-DCs) cells, whereas blockade of TGF-b partly reversed their inhibitory functions (Fig 6, B) .
Collectively, these findings demonstrate that Act-A-iTreg cell-modified DCs drive the expansion and de novo generation of Foxp3
1 Treg cells during priming with allergen in vivo. To obtain functional evidence that the antiallergic functions of Act-A-iTreg cell-modified DCs were mediated through induction of Foxp3
1 Treg cells, we used Foxp3 DTR transgenic mice (experimental protocol is shown in Fig E5, B) . 13 Depletion of Foxp3 1 Treg cells in mice transferred with Teff cell-modified DCs exacerbated the airway disease phenotype, as reflected by significantly increased T H 2 effector responses in the DLNs accompanied by enhanced inflammatory cell infiltration in the lungs and BAL fluid compared with that in non-Treg cell-depleted mice (Fig 7, A-D) . Interestingly, depletion of
Foxp3
1 Treg cells in mice transferred with Act-A-iTreg cell-modified DCs abolished the suppressive effects of the latter on airway inflammation, as shown by significantly increased numbers of eosinophils and heightened IL-4, IL-13, and IL-10 levels in the BAL fluid compared with those in nondepleted Act-A-iTreg cell-modified DC recipients (Fig 7,  A and B) . In addition, amelioration of leukocytic infiltration and mucus secretion in mice transferred with Act-AiTreg cell-modified DCs was reversed on Treg cell depletion (Fig 7, C) .
As expected, depletion of Foxp3 1 Treg cells in mice that received Teff cell-modified DCs resulted in enhanced DLN T-cell responses on allergen restimulation, as evidenced by significantly increased proliferation and increased IL-4, IL-13, and IL-10 release compared with values in non-Treg cell-depleted mice (Fig 7, D) . Of note, the inhibitory effects on DLN recall responses were abrogated on depletion of Foxp3
1
Treg cells in recipients of Act-A-iTreg cell-modified DCs (Fig 7, D) . OVA-specific IgE levels were also augmented in the sera of Foxp3 DTR mice transferred with Act-A-iTreg cell-modified DCs (Fig 7, E) . A, Experimental protocol used. B, BAL differentials from mice that received Act-A-iTreg cell-modified DCs or Teff cell-modified DCs or with PBS (allergic mice). Eos, Eosinophils; LMs, lymphocytes; Macs, macrophages; Neuts, neutrophils. C, DLN cells were restimulated with OVA. T-cell proliferation and cytokine levels are depicted. D, OVA-specific IgE levels in sera. Results are shown as means 6 SEMs of triplicate wells from 2 independent experiments (n 5 5-7 mice per group). Statistical significance was obtained by using the unpaired Student t test: *P < .05, **P < .01, and ***P < .001.
Overall, our data underscore an essential role for Foxp3 
PD-1/PD-L1 interactions are pivotal for generation of tolerogenic DCs by Act-A-iTreg cells
We next sought to elucidate the molecular mechanisms through which Act-A-iTreg cells induce generation of DCs with tolerogenic functions. Initially, we investigated the phenotype of Act-A-iTreg cells after transfer into BALB/c-Rag1 2/2 mice. Act-A-iTreg cells expressed increased levels of PD-1 and lymphocyte activation gene 3, whereas ICOS, GITR, Foxp3, and CTLA-4 were expressed at levels equivalent to those of Teff cells (Fig 8, A) . In concordance, PD-1 mRNA levels were increased in Act-A-iTreg cells (Fig 8, B) . PD-L1 was also upregulated in Act-A-iTreg cell-modified DCs, which is in keeping with the increased surface expression (Fig 2, A) .
In view of these findings, we hypothesized that PD-1/PDL-1 interactions would be involved in generation of Act-A-iTreg cell-modified DCs. To address this, we administered anti-PD-1 blocking antibody into BALB/c-Rag1 Results are shown as means 6 SEMs of triplicate wells from 2 to 3 independent experiments (n 5 3-5 mice per group). Statistical significance was obtained by using the unpaired Student t test: **P < .01 and ***P < .001.
and T H 2 cytokine release in mice transferred with Act-A-iTreg cell-modified and anti-PD-1-treated DCs compared with those in Act-A-iTreg cell-modified and immunoglobulin-treated DC recipients (Fig 8, C and D) .
DISCUSSION
Previous studies have shown that
natural Treg cells isolated from the peripheral blood of asthmatic patients do not endow DCs with immunoregulatory functions. 7 In the present studies we uncovered a novel biological function for Act-A-iTreg cells in instructing the generation of highly tolerogenic DCs that could be exploited for the design of new immunotherapies for allergic disorders. In fact, our findings reveal that Act-A-iTreg cells, on in vivo interaction with DCs, debilitate the T H 2 cell priming potential of the latter and endow them with strongly suppressive functions against T H 2 effector responses and hallmark asthma manifestations. Notably, Foxp3 Elegant studies have shown that bone marrow-derived dendritic cells (BM-DCs) exposed in vitro to IL-10 decreased airway hyperresponsiveness, airway eosinophilia, and T H 2 cytokine levels on transfer in a model of OVA-induced allergic airway inflammation. 27, 28 Similar results were obtained after administration of IL-10-stimulated house dust mite-loaded BM-DCs to house dust mite-sensitized and challenged mice. 29 Importantly, mice administered IL-10-treated BM-DCs in a tolerance-inducing protocol exhibited reduced allergic disease manifestations and T H 2 responses that remained suppressed for up to 8 months. 30 Still, these reports used high DC numbers and/or multiple dosing schemes to attain disease suppression, protocols that might preclude their use in clinical applications.
Remarkably, our findings demonstrate that a single administration of low numbers of Act-A-iTreg cell-modified DCs exert a dominant tolerogenic function on T H 2 responses and confers protection against experimental asthma. Moreover, of potential T-cell proliferation and cytokine release are depicted. E, OVA-specific IgE levels in sera are shown. Results are shown as means 6 SEMs (n 5 4-6 mice per group in 2 independent experiments). Statistical significance was obtained by using the unpaired Student t test: *P < .05, **P < .01, and ***P < .001.
J ALLERGY CLIN IMMUNOL VOLUME 141, NUMBER 2 clinical relevance, we showed that the immunoregulatory functions of DCs persisted even after the cessation of their interactions with Act-A-iTreg cells and were not overridden on transfer into the highly inflammatory milieu of allergic mice.
Considering that Foxp3
1 Treg cells were pivotal in mediating the suppressive effects of Act-A-iTreg cell-modified DCs, our findings raise the possibility that these cells can be also used for the therapeutic expansion, generation, or both of Foxp3 1 Treg cells.
Intriguingly, the present studies demonstrated that Act-A-iTreg cell-modified DCs displayed significantly reduced MHCII, CD80, and CD86 levels concomitant with decreased responsiveness to LPS signals in vivo, suggesting that Act-AiTreg cells control the DC maturation program. Seminal studies have shown that Foxp3 1 Treg cells downregulate CD80/CD86 on cDCs in a CTLA-4-and LFA-1-dependent manner, a process also used by human Foxp3 1 Treg cells. 31 Moreover, others have shown that Foxp3 1 Treg cells modulate DC functions through IL-10-induced expression of membrane-associated RING finger protein 1, an E3 ubiquitin ligase that degrades CD86 and MHCII. 9 Although our transcriptome analysis of Act-A-iTreg cell-modified DCs demonstrated increased levels of membraneassociated RING finger protein 3, another E3 ubiquitin ligase, these results were not confirmed by means of RT-PCR. Instead, mechanistic studies uncovered a key role for PD-1/PD-L1 signaling in endowing DCs with enhanced tolerogenic functions in response to Act-A-iTreg cells. In agreement, recent studies have underscored the importance of PD-1/PD-L1 interactions in the establishment of respiratory tolerance in neonatal and adult mice. [32] [33] [34] CCR7 was downregulated in Act-A-iTreg cell-modified DCs, a finding associated with their compromised capacity to traffic to the DLNs. These results reinforce and extend our previous observations, 12 suggesting that Act-A-iTreg cells suppress allergic airway inflammation in part through mitigating the migration of allergen-carrying DCs in the DLNs.
Notably, as documented in other studies, activin-A can exert proallergic effects when administered at low doses directly into the airways. 35 Hence it is conceivable that stimulation of CD4 Results are shown as means 6 SEMs of triplicate wells from 2 independent experiments (n 5 4-6 mice per group). Statistical significance was obtained by using the unpaired Student t test: *P < .05, **P < .01, and ***P < .001.
proallergic effects of activin-A on T-cell responses (unpublished observations). 12 Overall, it seems that activin-A, similar to other cytokines, can exert both proinflammatory and anti-inflammatory functions depending on the in vitro or in vivo system used, the anatomic location, the phase and magnitude of the immune response, and the cell activation status. 35 Despite extensive research, the precise transcriptional programs underlying the tolerance-inducing functions of DCs in the context of allergic responses remain largely unexplored. Interestingly, our transcriptional analyses revealed that Act-AiTreg cell-modified DCs displayed a marked reduction in expression of a constellation of genes associated with T H 2 cell-priming potential, including the TFs IRF4 and KLF4, T H 2 cytokines, chemokines, and their signaling pathways. In contrast, expression of lymphoid enhancer-binding factor 1, a GATA-3 repressor in naive CD4
1 T cells, was significantly enriched in Act-A-iTreg cell-modified DCs. 36, 37 IRF4 and KLF4 expression in DCs is essential for induction and maintenance of T H 2 cell responses. [38] [39] [40] Moreover, IRF4 controls several DC maturation programs, including MHCII, CD80/CD86, and CCR7 expression, and their antigen-presenting capacities. 41 Hence it is conceivable that Act-A-iTreg cells restrain DC responses partly through regulating an IRF4-associated gene expression program critical for the maintenance of their T H 2-skewing potential.
Vaccination strategies involving the therapeutic transfer of tolerogenic immune cells are being used increasingly to restrain detrimental self-reactive responses in autoimmune diseases; still, their use in the control of allergic responses has not been exploited. Our studies reveal that Act-A-iTreg cells can fuel the generation of DCs with enhanced tolerogenic functions that could be targeted for the re-establishment of tolerance and amelioration of the asthmatic disease phenotype.
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Key messages
d In vivo interactions of Act-A-iTreg cells with DCs suppress the immunogenic properties of the latter, as exemplified by an impaired capacity to uptake allergen and traffic to the DLNs and diminished T H 2 cell priming potential. Results were pooled from 2 independent experiments (n 5 3-4 mice per group). *P < .05 and **P < .01. 
